| Name | Title | Contact Details |
|---|
Green Tree School and Services (GTSS) is a nonprofit, state-licensed agency that provides education, therapeutic and clinical support to children ages 5-21 with Autism Spectrum Disorder and Severe Emotional Disability. GTSS only serves children whose disabilities are such that they are unable to succeed in a school- based special education program or participate in out of school activities. Rates of both diagnosis are growing, with 1 in 68 children currently affected by Autism and 1 in 78 children affected by Emotional Disability. GTSS’ philosophy is rooted in the belief that every child should have the opportunity to learn the academic, social, emotional, and vocational and life skills they need to achieve resiliency and succeed in their learning, living and working environments. GTSS has worked with children and young adults with special needs since 1957, marking over a half century of Transforming Lives and Impacting Communities. GTSS offers a variety of on-site and off-site services to children with special needs, both directly and through their home school or district. The Approved Private School educates children whose disabilities prevent them from succeeding in a traditional special education program. Specialists work with children, in small groups or individually, to help students meet individual goals. The Outpatient Clinic provides psychiatric evaluation, case management and medication management services to students at the school. Consulting Services, also called Green Tree Partnerships, is an education consulting cooperative created by GTSS. Staff work collaboratively with a school or district and take on the management of portion of that school or district’s special education program. Students who exhibit signs of autism or emotional disabilities, but do not have a complete or up to date Individual Educational Plan, can receive Diagnostic Services from GTSS.
MRI Interventions, Inc. is a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Since our inception in 1998, we have focused on research and product development in the field of interventional MRI. From 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling MRI-guided interventions and to build an intellectual property position. In 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. We have two product platforms. Our ClearPoint® system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. Our ClearTrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. Both systems utilize intra-procedural magnetic resonance imaging to guide the procedures. Both systems are designed to work in a hospital’s existing MRI suite. Our products are designed to provide a new, minimally invasive surgical approach for the benefit of large patient populations. Our ClearPoint system is designed to enable the delivery of therapies to treat certain neurological diseases. Our ClearTrace system is designed to deliver therapies to treat certain cardiac diseases. We believe that our two product platforms, subject to appropriate regulatory clearance and approval, will provide better patient outcomes, enable physicians and hospitals to treat more patients, and reduce costs to the healthcare system.
Resolution Health Strategies is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
Front Range Cancer Specialists is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.